Next-gen CAR-T, TCR play­er Au­to­lus gains $80M for clin­i­cal tri­al work

Au­to­lus has gone back to the well to draw up an $80 mil­lion C round de­signed to push the next-gen CAR-T play­er through a key test for its three lead pro­grams.

While look­ing to even­tu­al­ly leapfrog the lead­ing pi­o­neers like No­var­tis, which achieved the first OK for CAR-T just months ago, Au­to­lus has its sights set on es­tab­lish­ing proof-of-con­cept da­ta on three pro­grams: AU­TO2 in mul­ti­ple myelo­ma, AU­TO3 in dif­fuse large B cell lym­phoma and pe­di­atric acute lym­phoblas­tic leukemia and AU­TO4 in T-cell lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER